Selskabets formål er at udvikle idèer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller idèer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 720.1 mio. | -228 mio. | 1.3 mia. | -162.8 mio. | 1103 | |
CVR: 29918791
Previous names: CADENZA PARTNERS ApS, ASCENDIS PHARMA ApS
Compared to 130 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
registered with 90% ownership
Jean-Jacques Bienaime joined the board
Companies in the same industry and area
CVR 32323502
CVR 32323537
CVR 32323596
CVR 32323677
CVR 41034076
The financial health of ASCENDIS PHARMA A/S appears to be concerning, marked by significant losses and declining equity over the past few years. Revenue has shown a substantial increase from 7.8 million DKK in 2021 to 720.1 million DKK in 2025, but this growth has not translated into profitability, with losses reaching -228 million DKK in 2025. The company's equity has deteriorated from 883.6 million DKK in 2021 to -162.8 million DKK in 2025, raising concerns about its financial stability and ability to sustain operations. As it operates in the pharmaceutical manufacturing sector, the trajectory suggests a need for strategic adjustments to improve margins and address its negative equity position.
AI-generated summary
companydata.dk